Rani Therapeutics vs TherapeuticsMD
RANI and TXMD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RANI and TXMD compare
Rani Therapeutics is the larger company, worth 3.6 times as much as TherapeuticsMD ($75.3M against $20.9M).
Rani Therapeutics grew revenue faster over the last twelve months (306% versus 27.8% for TherapeuticsMD).
TherapeuticsMD keeps more of each dollar of sales as profit, with a net margin of −6.6% compared with −618% at Rani Therapeutics.
TherapeuticsMD scores higher on the StockData Score (12 against 3 for Rani Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RANI | TXMD |
|---|---|---|
| Size and price | ||
| Market cap | $75.3M | $20.9M |
| Share price | $0.540 | $1.81 |
| Change, 1 year | −72.0% | 11.7% |
| Change, 5 years | −98.2% | −93.8% |
| Beta (5Y) | 1.60 | 0.44 |
| Employees | 69 | 1 |
| StockData Score | ||
| Total score | 3 | 12 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 0 | 3 (better) |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.4× | 6.4× (better) |
| P/B | 1.9× | 0.8× (better) |
| FCF yield | −27.0% | – |
| Fair value | $0.388 | $2.56 |
| Margin of safety | −39.1% | 29.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 306% (better) | 27.8% |
| Revenue growth, 5Y average | 28.7% (better) | −45.8% |
| Profitability | ||
| Operating margin | −676% | −121% (better) |
| Net margin | −618% | −6.6% (better) |
| FCF margin | −417% | – |
| Return on equity | −179% | −0.80% (better) |
| Return on invested capital | −145% | −15.9% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −28.2× | – |
| Current ratio | 5.31 (better) | 3.22 |
| Altman Z-score | −0.67 (better) | −34.22 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 32.7% | 31.7% |
| Held by insiders | 30.6% | 1.6% |
| Insider net buying, 12 months | $49.7K (better) | $14.0K |
| Short interest, % of float | 8.5% | 0.27% |
Go deeper
- RANI stock overview
- RANI income statement
- RANI valuation and score
- TXMD stock overview
- TXMD income statement
- TXMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.